BRIEF-GSK gets Canadian approval for bronchodilator treatment Incruse
April 17 (Reuters) - Glaxosmithkline Plc :
* Glaxosmithkline plc gsk receives approval in Canada for incruse
* Announces approval in canada for Incruse Ellipta (Umeclidinium) as a treatment for COPD
* Has received market authorisation in Canada for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema
* Clinical programme for Umeclidinium included seven phase iii clinical trials which involved over 2,500 copd patients treated with umeclidinium or placebo Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.